Evidence map›Paper›PMID 22988559›Full record

ReviewAdvanced materials (Deerfield Beach, Fla.)2012

Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery.

Laura M Ensign, Craig Schneider, Jung Soo Suk, Richard Cone, Justin Hanes

Abstract readReview
In one paragraph

Review in Advanced materials (Deerfield Beach, Fla.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 279 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Innovative triamcinolone acetonide microsuspension for Non-Invasive ocular management of inflammation.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Nanomedicine for Maternal and Fetal Health.Small (Weinheim an der Bergstrasse, Germany) · 2024
    Review
  18. Article
  19. Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Laura M EnsignDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA.
Craig Schneider
Jung Soo Suk
Richard Cone
Justin Hanes
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Vector CoreP01HL051811 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI GUGGINO, WILLIAM B. · 1993 to 2013
$20.2M
ValidationU54CA151838 · NCI · JOHNS HOPKINS UNIVERSITY · PI MAITRA, ANIRBAN · 2010 to 2014
$11.9M
New Gene Vectors for Cystic Fibrosis (CF): Extra- & Intracellular BarriersR01EB003558 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S. · 2007 to 2010
$1.4M
Mucus-penetrating nanoparticles for sustained microbicide deliveryR33AI079740 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HANES, JUSTIN S. · 2010 to 2012
$1.4M
Mucus Penetrating Particles for Rectal MicrobicidesR33AI094519 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CONE, RICHARD, HANES, JUSTIN S. · 2013 to 2015
$1.4M
Mucus Penetrating Particles for Rectal MicrobicidesR21AI094519 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CONE, RICHARD, HANES, JUSTIN S. · 2011 to 2012
$440k
Howard Hughes Medical InstituteNCI NIH HHS U54 CA151838NCI NIH HHS U54CA151838NHLBI NIH HHS P01 HL051811NHLBI NIH HHS P01HL51811NIAID NIH HHS R21 AI094519NIAID NIH HHS R21AI094519NIAID NIH HHS R33 AI079740NIAID NIH HHS R33AI079740NIAID NIH HHS R33 AI094519NIBIB NIH HHS R01 EB003558NIBIB NIH HHS R01EB003558
6 · The paper itself

Abstract

A method that could provide more uniform and longer-lasting drug and gene delivery to mucosal surfaces holds the potential to greatly improve the effectiveness of prophylactic and therapeutic approaches for numerous diseases and conditions, including sexually transmitted infections, cystic fibrosis, chronic rhinosinusitis, inflammatory bowel disease, and glaucoma to name a few. However, the body's natural defenses, including adhesive, rapidly cleared mucus linings coating nearly all entry points to the body not covered by skin, has limited the effectiveness of drug and gene delivery by nanoscale delivery systems. This article discusses the recent development of the “mucuspenetrating particle” or “MPP” nanotechnology, and how it has been used to both enhance understanding of the nanoscale barrier properties of human mucus secretions, and to achieve more uniform and longer-lasting drug delivery to mucosal tissues following topical administration. Drug loaded MPPs possess non-adhesive coatings that allow them to rapidly penetrate mucus layers through openings in the mucus mesh at rates nearly as fast as they would penetrate pure water. Critically, MPPs allow enhanced drug and gene delivery to mucosal tissues without diminishing the protective function of mucus. Recent progress in the development of MPPs as a biophysical tool to probe the length-scale dependent rheological properties of mucosal secretions and as a method for drug and gene delivery is highlighted.

Indexed as

Drug Delivery SystemsGene Transfer TechniquesMucusNanoparticlesAdministration, TopicalAnimalsBiophysical PhenomenaHumansNanotechnology

Identifiers

PMID22988559
PMCPMC3710133
OpenAlexW2138513817

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.